Cancer will have no place to hide...
Myrio Therapeutics ("Myrio Tx") is about to revolutionize the field of immuno-oncology by enabling antibody-based therapies to attack targets that are inside cells such as mutated cancer-causing and viral proteins. Proteins inside cells are routinely broken down into peptides which are displayed on the cell surface by Major Histocompatibility Complex (MHC), the targets of T-Cells. Myrio Tx’s protein-display system can discover antibodies against difficult to hit targets such as peptide-MHC complexes. This ability increases the number of addressable cancer or viral targets by a factor of ten. Based on fully-human sequences, discovered antibodies can be formatted to fit any purpose, from targeting CAR-T cells, antibody-drug conjugates, bispecifics or traditional antibodies.

Myrio Tx's discovery platform can generate high affinity (low nM/pM) and highly selective scFv (antibody fragments) in a matter of days, allowing for rapid evaluation and optimization of product candidates. Myrio Tx is seeking partnerships to fully exploit the potential of its technology whilst also building an in-house portfolio of products.

Biotechnology

Health Care

Health Diagnostics

Therapeutics

Myrio Tx

Graeme Wald

Thomas Ulmer

Kevin Beasley

Gouri Betigeri

Matthew Beasley

Ben Kiefel

Myrio Tx

Org chart

Similar companies